Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus
Fig 6
Experimental design and serum neutralizing antibody responses to Zika VLP vaccination in NHPs.
(6A) Rhesus macaques (5 per group) were immunized on the indicated days with a dose titration of VLPs formulated with alum (20μg VLP/300μg alum; 5μg VLP/75μg alum; and 1.25μg VLP/18.8μg alum) or alum only (300μg) (black syringes), test bled (red drops), and challenged (gray syringe) on the days shown. (6B) Serum nAbs measured by PRNT50, (6C) microneutralization (MN50) assay, and (6D) Renilla luciferase (Rluc)-based ZIKV neutralization assay (RlucNT50). Test bleed time points are shown at top for each assay. GMTs are shown by bars, individual titers by symbols, and assay detection limits by dotted lines. Levels of significance between groups are shown by lines and were obtained by performing Kruskal-Wallis and Dunn’s pairwise comparison tests denoted by: ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05, or ns (not significant).